Efficacy studies
Our in vivo testing services encompass a wide range of efficacy assessments using a wide variety of models tailored to meet the diverse needs of our clients. From short-term Non-GLP Studies through preliminary screening and Comparative Tests, to advance studies towards clinical phase, we ensure thorough evaluation of potential treatments and products.
We specialize in establishing Dosing Regimens and accommodating special routes of administration, including uncommon routes and establishment of new models, to address specific research requirements.
- Comparative Tests with similar commercially available products allow for informed decision-making, among different formulations aimed at selecting the most suitable option while Proof of Concept (POC) tests validate the viability of novel interventions.
- Dose Range Finding (DRF) studies.
- Additionally, our capabilities extend to Administration – Distribution – Metabolism – Excretion (ADME) studies, facilitating a comprehensive understanding of drug behavior within the body.
Pharmacokinetics/Toxicokinetic studies provide essential insights into dosage optimization and drug metabolism.
Maximal Tolerated Dose (MTD) and Maximal Feasible Dose (MFD) studies ensure safety and efficacy boundaries are meticulously defined, supporting the development of effective and safe therapeutic interventions.
At HBI, we are committed to delivering exceptional efficacy testing solutions to drive biomedical innovation and improve patient outcomes.
For more information – contact us!